Cognitive
impairment is a
medical condition in which people lose their cognitive capabilities such as
thinking skills and memory. People having cognitive impairment are at high risk
of developing dementia or Alzheimer’s disease.
Cognitive impairment that
affects memory is known as amnestic mild cognitive impairment (MCI); and the
condition which affects thinking skills called nonamnestic MCI. Medical
professionals diagnose cognitive impairment by asking some questions which are
related to medical history, daily activities, for the assessment of the mental
status of the patients. Certain blood tests and brain structure’s imaging are
also used to diagnose cognitive impairment.
Request
to Get Free Sample Pages at:
AgeneBio
Inc., Heptares Therapeutics Ltd., Omeros Corporation, and Asceneuron SA are
some major companies involved in development of drugs for the management of
cognitive impairment. For instance, AgeneBio Inc. is in the process of
developing AGB101, a SV2A protein modulator, for the management of cognitive
impairment.
Access
Detailed Report Summary:
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Make
Enquiry Before Buying the Report:
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment